Harvard Bioscience Inc (HBIO): Next-Year EPS Estimate 269.74%
As of 2026-10-10, Harvard Bioscience Inc (HBIO) has a next-year EPS growth estimate of 269.74%. Featured in our EPS revision report on 2026-08-20.
On 2026-08-12, analyst consensus for HBIO's next-year EPS growth shifted from 169.34% to 269.74% — a positive change of 100.40 percentage points. The revised estimate has been sustained across 54 subsequent trading sessions. Current-year growth is projected at -90.00%.
What's Driving This
HBIO shares have risen primarily on a sharp upward revision to next-year EPS growth estimates, which analysts raised to 269.74% from 169.34% on August 12, 2026. That revision is consistent with the Q2 2026 earnings beat, the raised 2026 revenue guidance, and reported 11% revenue growth cited in recent coverage. Subsequent headlines largely repeat those
Generated 2026-10-10 from news as of 2026-10-10
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- EPS growth next year
- 269.74%
- EPS growth this year
- -90.00%
- EPS next quarter (est)
- -$0.17
- Last price
- $8.24
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-10 | 269.74% | -90.00% | -$0.17 | $8.24 |
| 2026-10-09 | 269.74% | -90.00% | -$0.17 | $8.24 |
| 2026-10-08 | 269.74% | -90.00% | -$0.17 | $8.13 |
| 2026-10-07 | 269.74% | -90.00% | -$0.17 | $8.50 |
| 2026-10-06 | 269.74% | -90.00% | -$0.17 | $8.56 |
| 2026-10-05 | 269.74% | -90.00% | -$0.17 | $8.50 |
| 2026-10-04 | 269.74% | -90.00% | -$0.17 | $8.34 |
| 2026-10-03 | 269.74% | -90.00% | -$0.17 | $8.34 |
| 2026-10-02 | 269.74% | -90.00% | -$0.17 | $8.34 |
| 2026-10-01 | 269.74% | -90.00% | -$0.17 | $8.13 |
| 2026-09-30 | 269.74% | -90.00% | -$0.17 | $7.92 |
| 2026-09-29 | 269.74% | -90.00% | -$0.17 | $7.96 |
| 2026-09-28 | 269.74% | -90.00% | -$0.17 | $7.98 |
| 2026-09-27 | 269.74% | -90.00% | -$0.17 | $7.96 |
| 2026-09-25 | 269.74% | -90.00% | -$0.17 | $7.96 |
| 2026-09-24 | 269.74% | -90.00% | -$0.17 | $8.02 |
| 2026-09-23 | 269.74% | -90.00% | -$0.17 | $8.05 |
| 2026-09-22 | 269.74% | -90.00% | -$0.17 | $7.92 |
| 2026-09-21 | 269.74% | -90.00% | -$0.17 | $8.00 |
| 2026-09-20 | 269.74% | -90.00% | -$0.17 | $7.95 |
| 2026-09-18 | 269.74% | -90.00% | -$0.17 | $7.95 |
| 2026-09-17 | 269.74% | -90.00% | -$0.17 | $8.03 |
| 2026-09-16 | 269.74% | -90.00% | -$0.17 | $7.97 |
| 2026-09-15 | 269.74% | -90.00% | -$0.17 | $8.00 |
| 2026-09-14 | 269.74% | -90.00% | -$0.17 | $8.09 |
| 2026-09-13 | 269.74% | -90.00% | -$0.17 | $8.03 |
| 2026-09-11 | 269.74% | -90.00% | -$0.17 | $8.03 |
| 2026-09-10 | 269.74% | -90.00% | -$0.17 | $8.15 |
| 2026-09-09 | 269.74% | -90.00% | -$0.17 | $7.95 |
| 2026-09-08 | 269.74% | -90.00% | -$0.17 | $7.95 |
Reports Featuring HBIO
Recent News
- Harvard Bioscience, Inc. Q2 2026 Earnings Call SummaryMoby
- Harvard Bioscience, Inc. Q2 2026 Earnings Call SummaryMoby
- Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...GuruFocus.com
- Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...GuruFocus.com
- Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidanceInvestorsHub
- Harvard Bioscience: Q2 Earnings SnapshotAssociated Press
- Harvard Bioscience Announces Second Quarter 2026 Financial ResultsGlobeNewswire
Screen Performance
Aggregate stats across all 2077 tickers our top-EPS-revision screen has flagged over the past 192 days.
- Median return since detection
- -0.9%
- % of tickers in the green
- 47%
- Median return on winners
- +23.2%
- Large revisions captured
- 1848
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Harvard Bioscience Inc's next-year EPS growth estimate?▾
As of 2026-10-10, Harvard Bioscience Inc (HBIO) has a next-year EPS growth estimate of 269.74%, based on analyst consensus.
When was the latest EPS estimate revision for HBIO?▾
The most recent revision occurred on 2026-08-12, when analysts adjusted the next-year EPS growth estimate from 169.34% to 269.74%.
What sector and industry does Harvard Bioscience Inc belong to?▾
Harvard Bioscience Inc operates in the Healthcare sector, specifically the Medical Instruments & Supplies industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. HBIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Harvard Bioscience Inc (HBIO) appears here because it was detected by our daily top-EPS-revision-performer screen.